# Generalized Myasthenia Gravis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/generalized-myasthenia-gravis

> 16 upcoming FDA catalysts in generalized Myasthenia Gravis: efgartigimod iv (ARGX) on March 2027 (primary completion); efgartigimod iv (ARGX) on Mar to Jun 2027 (topline data readout); APRIL (telitacicept, VOR) on March 2027 (primary completion); APRIL (telitacicept, VOR) on Mar to Jun 2027 (topline data readout); and 12 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 27, 2025 | [ALXN1720 primary completion](https://sec-api.dev/pdufa/alxn1720) | AZN | Generalized Myasthenia Gravis | completed | "NCT05556096 (Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-27 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05556096)) |
| July 8, 2025 | [Pozelimab + cemdisiran primary completion](https://sec-api.dev/pdufa/pozelimab-cemdisiran) | REGN | Generalized Myasthenia Gravis | completed | "NCT05070858 (A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-07-08 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05070858)) |
| Dec 2025 | [UPLIZNA® (inebilizumab) FDA approval](https://sec-api.dev/pdufa/inebilizumab) | AMGN | generalized myasthenia gravis | completed, approved | "In December 2025, we announced the FDA approved UPLIZNA for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) and anti-muscle specific tyrosine kinase (MuSK) antibody positive." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-20251231.htm)) |
| December 14, 2025 | [AMGEN INC PDUFA date](https://sec-api.dev/companies/amgn/catalysts) | AMGN | generalized myasthenia gravis | scheduled | "•U.S. Food and Drug Administration (FDA) review of the MINT Phase 3 data in patients with generalized myasthenia gravis is ongoing, with a PDUFA date of December 14, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815425000070/amgn-20250930earningsrelea.htm)) |
| March 2027 | [Efgartigimod iv primary completion](https://sec-api.dev/pdufa/efgartigimod-iv) | ARGX | Generalized Myasthenia Gravis | scheduled | "NCT04833894 (Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04833894)) |
| Mar to Jun 2027 | [Efgartigimod iv topline data readout](https://sec-api.dev/pdufa/efgartigimod-iv) | ARGX | Generalized Myasthenia Gravis | scheduled | "NCT04833894 (Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04833894)) |
| March 2027 | [APRIL (telitacicept) primary completion](https://sec-api.dev/pdufa/telitacicept) | VOR | Generalized Myasthenia Gravis | scheduled | "NCT06456580 (A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Vor Biopharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06456580)) |
| Mar to Jun 2027 | [APRIL (telitacicept) topline data readout](https://sec-api.dev/pdufa/telitacicept) | VOR | Generalized Myasthenia Gravis | scheduled | "NCT06456580 (A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Vor Biopharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06456580)) |
| Apr to Jul 2027 | [FABHALTA® (iptacopan) topline data readout](https://sec-api.dev/pdufa/iptacopan) | NVS | Generalized Myasthenia Gravis | scheduled | "NCT06517758 (A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06517758)) |
| April 2027 | [FABHALTA® (iptacopan) primary completion](https://sec-api.dev/pdufa/iptacopan) | NVS | Generalized Myasthenia Gravis | scheduled | "NCT06517758 (A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06517758)) |
| September 2027 | [Efgartigimod ph20 sc primary completion](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Generalized Myasthenia Gravis | scheduled | "NCT06392386 (A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06392386)) |
| Sep to Dec 2027 | [Efgartigimod ph20 sc topline data readout](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Generalized Myasthenia Gravis | scheduled | "NCT06392386 (A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06392386)) |
| December 2027 | [IMVT-1402 primary completion](https://sec-api.dev/pdufa/imvt-1402) | IMVT | Generalized Myasthenia Gravis | scheduled | "NCT07039916 (Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07039916)) |
| Dec 2027 to Mar 2028 | [IMVT-1402 topline data readout](https://sec-api.dev/pdufa/imvt-1402) | IMVT | Generalized Myasthenia Gravis | scheduled | "NCT07039916 (Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07039916)) |
| Feb to May 2028 | [Remibrutinib (blinded) topline data readout](https://sec-api.dev/pdufa/remibrutinib-blinded) | NVS | Generalized Myasthenia Gravis | scheduled | "NCT06744920 (A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-02-25 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06744920)) |
| February 2028 | [Remibrutinib (blinded) primary completion](https://sec-api.dev/pdufa/remibrutinib-blinded) | NVS | Generalized Myasthenia Gravis | scheduled | "NCT06744920 (A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-02-25 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06744920)) |
| Sep to Dec 2028 | [Felzartamab topline data readout](https://sec-api.dev/pdufa/felzartamab) | BIIB | Generalized Myasthenia Gravis | scheduled | "NCT07939802 (A Study to Learn About the Effects of Felzartamab on Daily Living Activities and Its Safety in Adults With Generalized Myasthenia Gravis (gMG) Ages 18 to 80 Years Old): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-09-19 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07939802)) |
| September 2028 | [Felzartamab primary completion](https://sec-api.dev/pdufa/felzartamab) | BIIB | Generalized Myasthenia Gravis | scheduled | "NCT07939802 (A Study to Learn About the Effects of Felzartamab on Daily Living Activities and Its Safety in Adults With Generalized Myasthenia Gravis (gMG) Ages 18 to 80 Years Old): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-09-19 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07939802)) |
| Mar to Jun 2030 | [UPLIZNA® (inebilizumab) topline data readout](https://sec-api.dev/pdufa/inebilizumab) | AMGN | Generalized Myasthenia Gravis | scheduled | "NCT06987539 (A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-03-13 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06987539)) |
| March 2030 | [UPLIZNA® (inebilizumab) primary completion](https://sec-api.dev/pdufa/inebilizumab) | AMGN | Generalized Myasthenia Gravis | scheduled | "NCT06987539 (A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-03-13 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06987539)) |

## Drugs

- [ALXN1720](https://sec-api.dev/pdufa/alxn1720) (AZN)
- [Pozelimab + cemdisiran](https://sec-api.dev/pdufa/pozelimab-cemdisiran) (REGN)
- [UPLIZNA® (inebilizumab)](https://sec-api.dev/pdufa/inebilizumab) (AMGN)
- [Efgartigimod iv](https://sec-api.dev/pdufa/efgartigimod-iv) (ARGX)
- [APRIL (telitacicept)](https://sec-api.dev/pdufa/telitacicept) (VOR)
- [FABHALTA® (iptacopan)](https://sec-api.dev/pdufa/iptacopan) (NVS)
- [Efgartigimod ph20 sc](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) (ARGX)
- [IMVT-1402](https://sec-api.dev/pdufa/imvt-1402) (IMVT)
- [Remibrutinib (blinded)](https://sec-api.dev/pdufa/remibrutinib-blinded) (NVS)
- [Felzartamab](https://sec-api.dev/pdufa/felzartamab) (BIIB)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/generalized-myasthenia-gravis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Generalized Myasthenia Gravis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/generalized-myasthenia-gravis

```bibtex
@misc{secapidev_indications_generalized_myasthenia_gravis_20261116,
  title        = {Generalized Myasthenia Gravis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/generalized-myasthenia-gravis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_generalized_myasthenia_gravis_20261116","title":"Generalized Myasthenia Gravis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/generalized-myasthenia-gravis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
